Phase 2Recruiting
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
A Phase II Study of IDH1 Inhibition With Ivosidenib as Maintenance Therapy After Ivosidenib, Azacitidine, and Venetoclax for Acute Myeloid Leukemia
- Sponsor
- Memorial Sloan Kettering Cancer Center (Academic or other)
- Enrolment
- 45 planned
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Ivosidenib; Azacitidine; Venetoclax
- Ages
- adults, older adults
- Registry
- NCT07392242
Full record on ClinicalTrials.gov
From the registry
The researchers are doing this study to find out whether a 3-drug combination of ivosidenib, azacitidine, and venetoclax followed by maintenance therapy with ivosidenib alone is an effective treatment approach for people with newly diagnosed acute myeloid leukemia (AML) that has an IDH mutation. Maintenance therapy is additional treatment given to help keep cancer from coming back after it has disappeared following the first course of treatment. The researchers will also look at the safety of the treatment approach and what kind of a time commitment it involves for participants.
Primary outcomes
- Event free survival
History
Primary completion expected
Last registry update
Registered
Started